Ophthalmology Doctors in Bolingbrook, IL Accepting Medicare

6 Ophthalmology doctors found. Showing 1 - 6

Bryan J Phillips, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 718 S Weber Road, Bolingbrook, IL 60490 Phone: 630-378-4799    Fax: 630-378-4783

Sujaya P Rupani, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 396 Remington Blvd, Suite 340, Bolingbrook, IL 60440 Phone: 630-759-9800    Fax: 630-759-9858

Dr. Dawn Renee Phillips, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 718 S Weber Road, Bolingbrook, IL 60490 Phone: 630-378-4799    Fax: 630-378-4783

Dr. Irma Ahmed, MD Ophthalmology - Retina Specialist Medicare: Accepting Medicare Assignments Practice Location: 550 E. Boughton Rd, Suite 120, Bolingbrook, IL 60440 Phone: 630-783-9960    Fax: 630-783-9962

Dr. Prakash Selvaraj, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 396 Remington Blvd, Suite 340, Bolingbrook, IL 60440 Phone: 630-759-9800

Rajakumari Prakash Selvaraj, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 393 Remington Blvd., Suite 340, Bolingbrook, IL 60440 Phone: 630-759-9800    Fax: 630-759-9858

News Archive

Study: E-cigarette users have 43% increased risk of developing respiratory disease

A growing body of evidence points to the health risks of using e-cigarettes (or "vaping"). But because e-cigarettes are marketed as a less harmful alternative to traditional cigarettes, it has been difficult to tell whether the association between vaping and disease is just a matter of smokers switching to vaping when they start experiencing health issues.

Lexicon to receive funding for LX4211 Phase 2 trial in type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that an independent, non-profit organization will provide funding to support the Phase 2 development of LX4211 in type 1 diabetes.

Ciclosporin no more effective than infliximab in severe UC

Ciclosporin and infliximab have similar efficacy for the treatment of patients with refractory severe ulcerative colitis, show the findings of a multinational trial.

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

From today, people in Scotland with the genetic kidney disease ADPKD could benefit from JINARC® (tolvaptan) following advice issued by the Scottish Medicines Consortium (SMC) for its use in adults with chronic kidney disease (CKD) stages 1-3 at the start of treatment with evidence of rapidly progressing disease.

Read more Medical News

› Verified 1 days ago